Abstract:Retinoid X receptor (RXR alpha) is a nuclear receptor (NR) for retinoic acid (RA) and regulates various NR signaling pathways. Ligand-binding domain (LBD) of RXR alpha can bind with its ligand 9-cis-RA and cofactors, and mediate the forming of homodimer and homotetramer of RXR alpha and its heterodimer with other NRs, conferring RXR alpha the ability to play complicated roles in development and diseases. Due to the coexistence of monomer, dimer and tetramer, there are difficulties to study the structure and interaction of RXR alpha-LBD with its ligands and cofactors in solution and to distinguish the roles of different forms of RXR alpha in cell. Here, through analyzing available structures of RXR alpha-LBD, we selected two residues, D379 and L420, in the homodimer interface to design three mutants of RXR alpha-LBD. Recombinant proteins of the three mutants showed decreased proportions of dimer and tetramer but unchanged overall structure and binding affinities to 9-cis-RA, corepressor SMRT, and coactivator SRC2. Especially, the double-site mutant RXR alpha-LBDD379A-L420G existed as a uniform monomer. Furthermore, L420 was found to play a similar role in forming RXR alpha-LBD homodimer and its heterodimer with various NRs, while the role of D379 varies a lot, as it shows almost no interaction with RAR alpha/b, LXR alpha/b, and THR alpha/b. This study provides a new insight into the mechanism for forming RXR alpha-LBD homodimer and its heterodimer with other NRs, and will facilitate the studies on the structure and interaction of RXR alpha-LBD with ligands, cofactors and drugs in solution, and the broad physiological functions of RXR alpha cooperating with various NRs in cell. (c) 2022 Elsevier Inc. All rights reserved.

Binding Characterization, Synthesis and Biological Evaluation of RXRα Antagonists Targeting the Coactivator Binding Site

Structural Basis for Retinoic X Receptor Repression on the Tetramer

Danthron Functions as a Retinoic X Receptor Antagonist by Stabilizing Tetramers of the Receptor

Recent Progress in the Design and Discovery of RXR Modulators Targeting Alternate Binding Sites of the Receptor

Identification of a New RXRα Antagonist Targeting the Coregulator-Binding Site.

Structure basis of bigelovin as a selective RXR agonist with a distinct binding mode.

Design, synthesis and biological evaluations of novel farnesoid X receptor (FXR) agonists

Nitrostyrene Derivatives Act as RXRα Ligands to Inhibit TNFα Activation of NF-κB.

Virtual Screening and Experimental Validation Identify Novel Modulators of Nuclear Receptor RXRα from Drugbank Database.

Structure-based Discovery of New Modulators Targeting Nuclear X Receptor Alpha for Cancer Therapy

Regulation of the Nongenomic Actions of Retinoid X Receptor-Α by Targeting the Coregulator-Binding Sites

Structural basis for the full and partial agonist activities of retinoid X receptor α ligands with an iso-butoxy and an isopropyl group

Synthesis and SAR Study of Modulators Inhibiting Trxrα-Dependent AKT Activation.

Tuning RXR Modulators for PGC1α Recruitment

Structure-guided design of a highly potent RXR agonist with superior physicochemical properties

The Effect of Antagonists on the Conformational Exchange of the Retinoid X Receptor Alpha Ligand-Binding Domain

A Structure-based Approach to Retinoid X Receptor-α Inhibition

Design, Synthesis and Biological Evaluation of Tetrazole-Containing RXRα Ligands As Anticancer Agents.

Mutation of Two Residues Converts the Ligand-Binding Domain of RXRα into a Uniform Monomer Without Impairing the Binding of Retinoic Acid and Cofactors.

Determinants of retinoid X receptor transcriptional antagonism.

Function Annotation of Hepatic Retinoid X Receptor Α Based on Genome-Wide DNA Binding and Transcriptome Profiling.